Physician profile
David Rhine
NPI 1134377435
$6,297.61
in general payments reported to CMS, 2019-2025
18 companies · $650 in 2025
The $650 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $911 · 2020: $563 · 2021: $441 · 2022: $1,040 · 2023: $2,636 · 2024: $56.42 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,854 · Consulting Fee: $489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,853.52 |
| Consulting Fee | $489.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,519.47 | 2021-2025 | Micra, Linq II, Azure Xt Dr Mri Surescan |
| Biosense Webster, INC. | $1,257.36 | 2019-2025 | Carto 3, Nuvision Ice Catheter |
| Medtronic Vascular, INC. | $706.11 | 2019-2020 | |
| Boston Scientific Corporation | $616.40 | 2019-2025 | Intellamap Orion, Farapulse, Emblem Mri S-Icd |
| Philips North America LLC | $312.09 | 2019-2022 | |
| Amgen INC. | $207.38 | 2020-2023 | Repatha |
| Abbott Laboratories | $177.16 | 2022-2023 | Gallant |
| E.R. Squibb & Sons, L.L.C. | $95.87 | 2021-2023 | Camzyos |
| Inari Medical, INC. | $75.26 | 2020 | |
| Amarin Pharma, INC. | $58.26 | 2021 | |
| Preventice Services, LLC | $52.06 | 2020 | |
| Janssen Pharmaceuticals, INC | $50.71 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $50.68 | 2021-2023 | Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.43 | 2023 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $31.39 | 2021-2023 | Lifevest |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $19.87 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $13.75 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rhine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.